Triglyceride-glucose index is prospectively associated with chronic kidney disease progression in Type 2 diabetes – mediation by pigment epithelium-derived factor
Diabetes and Vascular Disease Research · 2022-07 · 19 (4)
DOI: 10.1177/14791641221113784 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes and Vascular Disease Research, online erschienen am 08.08.2022. Verfasst von Serena Low und 10 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Centre, 609710Admiralty Medical Centre, Singapore. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Medical Research Council.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Triglyceride-glucose (TyG) index is a surrogate marker of insulin resistance. Its role in chronic kidney disease (CKD) progression in Type 2 Diabetes Mellitus (T2DM) is unclear. We investigated the association between TyG index and CKD progression, and possible mediation of the association by pigment epithelium-derived factor (PEDF).
Methods
This was a prospective study on 1571 patients with T2DM. CKD progression was defined as worsening across KDIGO estimated glomerular filtration rate (eGFR) categories with ≥25% reduction from baseline. PEDF was quantitated using enzyme-linked immunosorbent assay method. Cox proportional hazards regression model was used to assess the relationship between TyG index and CKD progression.
Results
Over a follow-up period of up to 8.6 years (median 4.6 years, IQR 3.0–3.6), 42.7% of subjects had CKD progression. Every unit increase in TyG was associated with hazards of 1.44 (95%CI 1.29–1.61; p < 0.001) in unadjusted analysis and 1.21 (1.06–1.37; p = 0.004) in fully adjusted model. Compared to tertile 1, tertiles 2 and 3 TyG index were positively associated with CKD progression with corresponding hazard ratios HRs 1.24 (1.01–1.52; p = 0.037) and 1.37 (1.11–1.68; p = 0.003) in fully adjusted models. PEDF accounted for 36.0% of relationship between TyG index and CKD progression.
Conclusions
Higher TyG index independently predicted CKD progression in T2DM. PEDF mediated the association between TyG index and CKD progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes Centre, 609710Admiralty Medical Centre, Singapore.
- Clinical Research Unit, 150819Khoo Teck Puat Hospital, Singapore.
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
- 63707National Healthcare Group Polyclinics, Singapore.
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
ORCID-Profile: Tavintharan Subramaniam
Förderung
- National Medical Research Council
Zitieren
APA
Low, S., Pek, S., Moh, A., Ang, K., Khoo, J., Shao, Y. M., Tang, W. E., Lim, Z., Subramaniam, T., Sum, C. F., & Lim, S. C. (2022). Triglyceride-glucose index is prospectively associated with chronic kidney disease progression in Type 2 diabetes – mediation by pigment epithelium-derived factor. Diabetes and Vascular Disease Research, 19(4). https://doi.org/10.1177/14791641221113784
Vancouver
Low S, Pek S, Moh A, Ang K, Khoo J, Shao YM, et al. Triglyceride-glucose index is prospectively associated with chronic kidney disease progression in Type 2 diabetes – mediation by pigment epithelium-derived factor. Diabetes and Vascular Disease Research. 2022;19(4). doi:10.1177/14791641221113784
BibTeX
@article{Low2022,
author = {Low, Serena and Pek, Sharon and Moh, Angela and Ang, Keven and Khoo, Jonathon and Shao, Yi-Ming and Tang, Wern E and Lim, Ziliang and Subramaniam, Tavintharan and Sum, Chee F and Lim, Su C},
title = {Triglyceride-glucose index is prospectively associated with chronic kidney disease progression in Type 2 diabetes – mediation by pigment epithelium-derived factor},
journal = {Diabetes and Vascular Disease Research},
year = {2022},
volume = {19},
number = {4},
doi = {10.1177/14791641221113784}
}
EUVIMED